MX2009012182A - Sales novedosas de piperazina como antagonistas d3/d2. - Google Patents

Sales novedosas de piperazina como antagonistas d3/d2.

Info

Publication number
MX2009012182A
MX2009012182A MX2009012182A MX2009012182A MX2009012182A MX 2009012182 A MX2009012182 A MX 2009012182A MX 2009012182 A MX2009012182 A MX 2009012182A MX 2009012182 A MX2009012182 A MX 2009012182A MX 2009012182 A MX2009012182 A MX 2009012182A
Authority
MX
Mexico
Prior art keywords
antagonists
salts
piperazine salts
novel piperazine
solvates
Prior art date
Application number
MX2009012182A
Other languages
English (en)
Inventor
Gyoergy Domany
Istvan Greiner
Eva Againe Csongor
Laszlo Czibula
Ferenc Seboek
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MX2009012182A publication Critical patent/MX2009012182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a sales novedosas monoclorhidrato, diclorhidrato, monohidrobromuro, maleato y metansulfonato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il] -etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o sus hidratos y/o solvatos. Además, la invención se refiere al proceso para la preparación de sales y sus hidratos y/o solvatos, a su uso en el tratamiento y/o prevención de trastornos que requieren la modulación del receptor de dopamina y a composiciones farmacéuticas que las contienen.
MX2009012182A 2007-05-11 2008-05-13 Sales novedosas de piperazina como antagonistas d3/d2. MX2009012182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700339A HU230748B1 (hu) 2007-05-11 2007-05-11 Új piperazin só és előállítási eljárása
PCT/HU2008/000044 WO2008139235A2 (en) 2007-05-11 2008-05-13 Novel piperazine salts as d3/d2 antagonists

Publications (1)

Publication Number Publication Date
MX2009012182A true MX2009012182A (es) 2009-12-09

Family

ID=89987512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012182A MX2009012182A (es) 2007-05-11 2008-05-13 Sales novedosas de piperazina como antagonistas d3/d2.

Country Status (35)

Country Link
US (1) US7943621B2 (es)
EP (1) EP2155696B1 (es)
JP (1) JP2010526861A (es)
KR (2) KR20100018493A (es)
CN (1) CN101679315B (es)
AP (1) AP2009005012A0 (es)
AU (1) AU2008249772B2 (es)
BR (1) BRPI0811199A2 (es)
CA (1) CA2684404C (es)
CO (1) CO6241112A2 (es)
CY (1) CY1119076T1 (es)
DK (1) DK2155696T3 (es)
EA (1) EA017270B1 (es)
EC (1) ECSP099772A (es)
ES (1) ES2628025T3 (es)
GE (1) GEP20125522B (es)
HK (1) HK1140473A1 (es)
HR (1) HRP20170918T1 (es)
HU (2) HU230748B1 (es)
IL (1) IL201533A0 (es)
LT (1) LT2155696T (es)
MA (1) MA31434B1 (es)
MX (1) MX2009012182A (es)
MY (1) MY148078A (es)
NI (1) NI200900203A (es)
NZ (1) NZ580642A (es)
PL (1) PL2155696T3 (es)
PT (1) PT2155696T (es)
RS (1) RS56036B1 (es)
SI (1) SI2155696T1 (es)
TN (1) TN2009000458A1 (es)
TW (1) TWI424846B (es)
UA (1) UA102225C2 (es)
WO (1) WO2008139235A2 (es)
ZA (1) ZA200907511B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017732B1 (ru) * 2007-05-11 2013-02-28 Рихтер Гедеон Нирт. Сольватная и кристаллическая формы гидрохлорида транс-1{4-[2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил]циклогексил}-3,3-диметилмочевины, способы их получения и их применение в фармацевтических композициях и способах лечения состояний, для которых необходима модуляция дофаминовых рецепторов
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
EA018064B1 (ru) * 2007-08-03 2013-05-30 Рихтер Гедеон Нирт. Способ лечения депрессии
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
EA023972B1 (ru) * 2008-02-21 2016-08-31 Рихтер Гедеон Нирт. Стабильный твёрдый препарат карипразина для перорального введения и способ его получения
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105B (zh) * 2015-09-22 2019-10-11 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP2023540056A (ja) 2020-08-26 2023-09-21 上海雲晟研新生物科技有限公司 カリプラジン薬用塩及びその結晶形、製造方法及び応用
WO2023077094A1 (en) * 2021-10-28 2023-05-04 Abbvie Inc. Treatment of major depressive disorder
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TW201002323A (en) 2010-01-16
HU0700339D0 (en) 2007-07-30
WO2008139235A8 (en) 2009-12-03
DK2155696T3 (en) 2017-07-10
CA2684404C (en) 2013-02-05
CA2684404A1 (en) 2008-11-20
HU230748B1 (hu) 2018-02-28
ES2628025T3 (es) 2017-08-01
US20090023750A1 (en) 2009-01-22
PT2155696T (pt) 2017-06-02
BRPI0811199A2 (pt) 2014-10-29
HRP20170918T1 (hr) 2017-09-22
CY1119076T1 (el) 2018-01-10
AU2008249772B2 (en) 2013-09-05
MY148078A (en) 2013-02-28
JP2010526861A (ja) 2010-08-05
UA102225C2 (ru) 2013-06-25
TWI424846B (zh) 2014-02-01
RS56036B1 (sr) 2017-09-29
KR20100018493A (ko) 2010-02-17
GEP20125522B (en) 2012-05-25
AP2009005012A0 (en) 2009-10-31
US7943621B2 (en) 2011-05-17
SI2155696T1 (sl) 2017-08-31
KR101668973B1 (ko) 2016-10-24
HUP0700339A2 (en) 2009-04-28
MA31434B1 (fr) 2010-06-01
CN101679315A (zh) 2010-03-24
AU2008249772A1 (en) 2008-11-20
LT2155696T (lt) 2017-06-12
EP2155696B1 (en) 2017-03-22
NI200900203A (es) 2010-03-11
EA017270B1 (ru) 2012-11-30
WO2008139235A3 (en) 2009-03-12
HK1140473A1 (en) 2010-10-15
WO2008139235A2 (en) 2008-11-20
HUP0700339A3 (en) 2010-01-28
KR20150090264A (ko) 2015-08-05
HUE034796T2 (en) 2018-03-28
ECSP099772A (es) 2009-12-28
PL2155696T3 (pl) 2017-10-31
TN2009000458A1 (en) 2011-03-31
CO6241112A2 (es) 2011-01-20
CN101679315B (zh) 2013-06-12
EA200971046A1 (ru) 2010-04-30
EP2155696A2 (en) 2010-02-24
NZ580642A (en) 2012-02-24
ZA200907511B (en) 2010-07-28
IL201533A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
MY148078A (en) Novel piperazine salts as d3/d2 antagonists
MY148643A (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
MY150784A (en) Metabolites of (thio) carbamoyl-cyclohexane derivatives
MY158648A (en) Compositions for modulating a kinase cascade and methods of use thereof
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MY155570A (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
MX2021000342A (es) Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimeti lcarbamoil-ciclohexilamina para el tratamiento de sintomas negativos de la esquizofrenia.
MX2009012126A (es) 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7.
TW200726764A (en) N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
MX2021002111A (es) Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
SI2185155T1 (en) Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors
MX2015008502A (es) Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.
MX2017003439A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales.
MX2010003986A (es) Antagonistas del receptor 5-ht7.
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
MX2020008745A (es) Derivados nuevos de indol y bencimidazol como antagonistas de los receptores 5-ht2a y 5-ht6.
HUP0302751A2 (hu) Kombinált 5-HT1A receptor agonista és szerotonin újrafelvételt gátló hatású vegyületek új alkalmazásai
CU20090190A7 (es) Sales novedosas de piperazina como antagonistas d3/d2
TH131527B (th) เกลือไพเพอราซีนชนิดใหม่ซึ่งเป็น d3/d2 แอนทาโกนิสต์

Legal Events

Date Code Title Description
FG Grant or registration